痛风

Choi HK, Atkinson K, Karlson EW, et al. Purine-rich foods, dairy and protein intake and the risk of gout in men. N Engl J Med. 2004;350:1093-1103.

• 全文
• 摘要

Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med. 2005;143:499-516.

• 摘要

Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65:1301-1311.

• 摘要

1.  Abbott RD, Brand FN, Kannel WB, et al. Gout and coronary heart disease: the Framingham Study. J Clin Epidemiol. 1988;41:237-242.

• 摘要

2.  Choi HK, Atkinson K, Karlson EW, et al. Purine-rich foods, dairy and protein intake and the risk of gout in men. N Engl J Med. 2004;350:1093-1103.

• 全文
• 摘要

3.  Mikuls TR, Farrar JT, Bilker WB, et al. Gout epidemiology: results from the UK general practice research database, 1990-1999. Ann Rheum Dis. 2005;64:267-272.

• 全文
• 摘要

4.  Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney Dis. 2002;40:37-42.

• 摘要

5.  Annemans L, Spaepen E, Gaskin M, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice. Annals Rheum Dis. 2008;67:960-966.

• 全文
• 摘要

6.  Bieber JD, Terkeltaub RA. Gout: on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum. 2004;50:2004-2014.

• 摘要

7.  Klemp P, Stansfield SA, Castle B, et al. Gout is on the increase in New Zealand. Ann Rheum Dis. 997;56:22-26.

• 全文
• 摘要

8.  Arromdee E, Michet CJ, Crowson CS, et al. Epidemiology of gout: is the incidence rising? J Rheumatol. 2002;29:2403-2406.

• 摘要

9.  Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987;82:421-426.

• 摘要

10.  Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med. 2005;143:499-516.

• 摘要

11.  Choi HK, Atkinson K, Karlson EW, et al. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the Health Professionals Follow-up Study. Arch Intern Med. 2005;165:742-748.

• 全文
• 摘要

12.  Lee J, Sparrow D, Vokonas PS, et al. Uric acid and coronary heart disease risk: evidence for a role of uric acid in obesity-insulin resistance syndrome. The Normative Aging Study. Am J Epidemiol. 1995;142:288-294.

• 摘要

13.  Johnson RJ, Rideout BA. Uric acid and diet - insights into the epidemic of cardiovascular disease. N Engl J Med. 2004;350:1071-1073.

• 摘要

14.  Wu XW, Lee CC, Muzny DM, et al. Urate oxidase: primary structure and evolutionary implications. Proc Natl Acad Sci USA. 1989;86:9412-9416.

• 全文
• 摘要

15.  Wu XW, Muzny DM, Lee CC, et al. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol. 1992;34:78-84.

• 摘要

16.  Richette P, Bardin T. Gout. Lancet. 2010;375:318-328.

• 摘要

17.  Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51:321-325.

• 全文
• 摘要

18.  Fam AG, Stein J, Rubenstein J. Gouty arthritis in nodal osteoarthritis. J Rheumatol. 1996;23:684-689.

• 摘要

19.  Yagnik DR, Hillyer P, Marshall D, et al. Noninflammatory phagocytosis of monosodium urate monohydrate crystals by mouse macrophages. Implications for the control of joint inflammation in gout. Arthritis Rheum. 2000;43:1779-1789.

• 全文
• 摘要

20.  Cronstein BN, Molad Y, Reibman J, et al. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest. 1995;96:994-1002.

• 全文
• 摘要

21.  Terkeltaub R, Zachariae C, Santoro D, et al. Monocyte-derived neutrophil chemotactic factor/interleukin-8 is a potential mediator of crystal-induced inflammation. Arthritis Rheum. 1991;34:894-903.

• 摘要

22.  Nishimura A, Akahoshi T, Takahashi M, et al. Attenuation of monosodium urate crystal-induced arthritis in rabbits by a neutralizing antibody against interleukin-8. J Leukoc Biol. 1997;62:444-449.

• 摘要

23.  Martinon F, Pétrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237-241.

• 摘要

24.  Terkeltaub R, Schumacher HR Jr, Saag KG, et al. Evaluation of rilonacept for prevention of gout flares during initiation of urate-lowering therapy: results of a phase 3, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62(suppl):152.

• 全文

25.  Terkeltaub R, Schumacher HR Jr, Curtis C, et al. Evaluation of rilonacept in patients with gouty arthritis experiencing an acute gout attack. Arthritis Rheum. 2010;62(suppl):153.

• 全文

26.  Schlesinger N, Lin HY, De Meulemeester M, et al. Efficacy of canakinumab (ACZ885), a fully human anti-interleukin (IL)-1beta monoclonal antibody, in the prevention of flares in gout patients initiating allopurinol therapy. Arthritis Rheum. 2010;62(suppl):2087.

• 全文

27.  So A, De Meulemeester M, Pikhlak A, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum. 2010;62:3064-3076.

• 摘要

28.  Liu R, Liote F, Rose DM, et al. Proline-rich tyrosine kinase 2 and Src kinase signaling transduce monosodium urate crystal-induced nitric oxide production and matrix metalloproteinase 3 expression in chondrocytes. Arthritis Rheum. 2004;50:247-258.

• 全文
• 摘要

29.  Bouchard L, de Medicis R, Lussier A, et al. Inflammatory microcrystals alter the functional phenotype of human osteoblast-like cells in vitro: synergism with IL-1 to overexpress cyclooxygenase-2. J Immunol. 2002;168:5310-5317.

• 全文
• 摘要

30.  Singh JA, Reddy SG, Kundukulam J. Risk factors for gout and prevention: a systematic review of the literature. Curr Opin Rheumatol. 2011;23:192-202.

• 摘要

31.  Choi HK, Atkinson K, Karlson EW, et al. Alcohol intake and risk of incident gout in men: a prospective study. Lancet. 2004;363:1277-1281.

• 摘要

32.  Oxford textbook of rheumatology. 2nd ed. Oxford: Oxford University Press; 1998.

33.  Glynn RJ, Campion EW, Silbert JE. Trends in serum uric acid levels 1961-1980. Arthritis Rheum. 1983;26:87-93.

• 摘要

34.  Emmerson B. Hyperlipidaemia in hyperuricaemia and gout. Ann Rheum Dis. 1998;57:509-510.

• 全文
• 摘要

35.  Rathmann W, Funkhouser E, Dyer AR, et al. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary Artery Risk Development in Young Adults. Ann Epidemiol. 1998;8:250-261.

• 摘要

36.  Dessein PH, Shipton EA, Stanwix AE, et al. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis. 2005;59:539-543.

• 全文
• 摘要

37.  Yamashita S, Matsuzawa Y, Tokunaga K, et al. Studies on the impaired metabolism of uric acid in obese subjects: marked reduction of renal urate excretion and its improvement by a low-calorie diet. Int J Obes. 1986;10:255-264.

• 摘要

38.  Ter Maaten JC, Voorburg A, Heine RJ, et al. Renal handling of urate and sodium during acute physiological hyperinsulinaemia in healthy subjects. Clin Sci (Lond). 1997;92:51-58.

• 摘要

39.  Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002;417:447-452.

• 摘要

40.  Prebis JW, Gruskin AB, Polinsky MS, et al. Uric acid in childhood essential hypertension. J Pediatr. 1981;98:702-707.

• 摘要

41.  Baker JF, Krishnan E, Chen L, et al. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med. 2005;118:816-826.

• 摘要

42.  Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20:895-900.

• 摘要

43.  Neogi T, Jansen TL, Dalbeth N, et al. 2015 gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol. 2015;67:2557-2568.

• 全文
• 摘要

44.  Neogi T, Jansen TL, Dalbeth N, et al. 2015 gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015;74:1789-1798.

• 全文
• 摘要

45.  Mushtaq S, Choudhary R, Scanzello CR. Non-surgical treatment of osteoarthritis-related pain in the elderly. Curr Rev Musculoskelet Med. 2011;4:113-122.

• 全文

46.  Neustadt DH. Intra-articular injections for osteoarthritis of the knee. Cleve Clin J Med. 2006;73:897-898, 901-904, 906-911.

47.  Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65:1301-1311.

• 摘要

48.  Ogdie A, Taylor WJ, Weatherall M, et al. Imaging modalities for the classification of gout: systematic literature review and meta-analysis. Ann Rheum Dis. 2015;74:1868-1874.

• 摘要

49.  Chowalloor PV, Siew TK, Keen HI. Imaging in gout: a review of the recent developments. Ther Adv Musculoskelet Dis. 2014;6:131-143.

• 全文
• 摘要

50.  Kozin F, McCarty DJ. Rheumatoid factor in the serum of gouty patients. Arthritis Rheum. 1977;20:1559-1560.

• 摘要

51.  Niewold TB, Harrison MJ, Paget SA. Anti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis. QJM. 2007;100:193-201.

• 全文

52.  Ory PA, Gladman DD, Mease PJ. Psoriatic arthritis and imaging. Ann Rheum Dis. 2005;64(suppl 2):ii55-ii57.

• 全文
• 摘要

53.  Terkeltaub R, Furst RE, Bennett K, et al. Colchicine efficacy assessed by time to 50% reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the AGREE trial. Abstract presented at: American College of Rheumatology Scientific Meeting; October 2009; Philadelphia, PA.

54.  Curiel RV, Guzman NJ. Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review. Semin Arthritis Rheum. 2012;42:166-178.

• 摘要

55.  Rainer TH, Cheng CH, Janssens HJ, et al. Oral prednisolone in the treatment of acute gout: a pragmatic, multicenter, double-blind, randomized trial. Ann Intern Med. 2016;164:464-471.

• 摘要

56.  Moi JH, Sriranganathan MK, Edwards CJ, et al. Lifestyle interventions for chronic gout. Cochrane Database Syst Rev. 2013;(5):CD010039.

• 全文
• 摘要

57.  Stamp LK, Taylor WJ, Jones PB, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012;64:2529-2536.

• 摘要

58.  Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64:1431-1446.

• 摘要

59.  Dubreuil M, Zhu Y, Zhang Y, et al. Allopurinol initiation and all-cause mortality in the general population. Ann Rheum Dis. 2015;74:1368-1372.

• 全文
• 摘要

60.  Qaseem A, Harris RP, Forciea MA, et al. Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016 Nov 1 [Epub ahead of print].

• 全文
• 摘要

61.  Yang CY, Chen CH, Deng ST, et al. Allopurinol use and risk of fatal hypersensitivity reactions: a nationwide population-based study in Taiwan. JAMA Intern Med. 2015;175:1550-1557.

• 摘要

62.  National Institute for Health and Care Excellence. Febuxostat for the management of hyperuricaemia in people with gout. December 2008 [internet publication].

• 全文

63.  Ernst ME, Fravel MA. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout. Clin Ther. 2009;31:2503-2518.

• 摘要

64.  Stevenson M, Pandor A. Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal. Health Technol Assess. 2009;13(Suppl 3):37-42.

• 摘要

65.  Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450-2461.

• 全文
• 摘要

66.  Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59:1540-1548.

• 全文
• 摘要

67.  Becker MA, Schumacher HR, MacDonald PA, et al. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36:1273-1282.

• 摘要

68.  US Food and Drug Administration. FDA adds Boxed Warning for increased risk of death with gout medicine Uloric (febuxostat). 21 February 2019 [internet publication].

• 全文

69.  White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018 Mar 12;378(13):1200-10.

• 全文
• 摘要

70.  Saag K, Fitz-Patrick D, Kopicko J, et al. FRI0320 lesinurad, a selective uric acid reabsorption inhibitor, in combination with allopurinol: results from a phase III study in gout patients having an inadequate response to standard of care (Clear 1). Ann Rheum Dis. 2015;74:540.

• 全文

71.  Bardin T, Keenan R, Khanna P, et al. FRI0333 lesinurad, a selective uric acid reabsorption inhibitor, in combination with allopurinol: results from a phase III study in gout patients having an inadequate response to standard of care (Clear 2). Ann Rheum Dis. 2015;74:545.

• 全文

72.  Dalbeth N, Jones G, Terkeltaub R, et al. SAT0329 lesinurad, a novel selective uric acid reabsorption inhibitor, in combination with febuxostat, in patients with tophaceous gout: the crystal phase III clinical trial. Ann Rheum Dis. 2015;74:778.

• 全文

73.  Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306:711-720.

• 全文
• 摘要

74.  Baraf H, Gutierrez-Urena SR, Vazquez-Mellado J, et al. Progressive reduction in tophus burden with pegloticase therapy in patients with chronic gout refractory to conventional therapy. Arthritis Rheum. 2010;62(suppl):157.

• 全文

75.  Schumacher HR Jr, Boice JA, Daikh DI, et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ. 2002;324:1488-1492.

• 全文
• 摘要

76.  Rubin BR, Burton R, Navarra S, et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum. 2004;50:598-606.

• 全文
• 摘要

77.  Gutierrez-Macias A, Lizarralde-Palacios E, Martinez-Odriozola P, et al. Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia. BMJ. 2005;331:623-624.

• 摘要

78.  Schumacher HR Jr, Sundy JS, Terkeltaub R, et al. Placebo-controlled study of rilonacept for gout flare prophylaxis during initiation of urate-lowering therapy. Abstract presented at: American College of Rheumatology Scientific Meeting; October 2009; Philadelphia, PA. http://acr.confex.com (last accessed 10 October 2016).

• 全文

79.  Sundy JS, Schumacher HR, Kivitz A, et al. Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study. J Rheumatol. 2014;41:1703-1711.

• 摘要

80.  Mitha E, Schumacher HR, Fouche L, et al. Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. Rheumatology (Oxford). 2013;52:1285-1292.

• 全文
• 摘要

81.  Schlesinger N, De Meulemeester M, Pikhlak A, et al. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat gouty arthritis by suppressing inflammation: results of a randomized, dose-ranging study. Arthritis Res Ther. 2011;13:R53.

• 全文
• 摘要

82.  Schlesinger N, Mysler E, Lin HY, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis. 2011;70:1264-1271.

• 全文
• 摘要

83.  Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012;71:1839-1848.

• 摘要

84.  National Institute for Health and Care Excellence. Canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks (terminated appraisal). April 2013. https://www.nice.org.uk (last accessed 10 October 2016).

• 全文

85.  Poiley J, Steinberg AS, Choi YJ, et al. A randomized, double-blind, active- and placebo-controlled efficacy and safety study of arhalofenate for reducing flare in patients with gout. Arthritis Rheumatol. 2016;68:2027-2034.

• 全文
• 摘要

86.  Fitz-Patrick D, Drummond W, Pappas J, et al. Effects of a purine nucleoside phosphorylase inhibitor, BCX4208, on the serum uric acid concentrations in patients with gout. Arthritis Rheum 2010;62(suppl):150.

• 全文

87.  Yu TF, Gutman AB. Efficacy of colchicine prophylaxis in gout. Prevention of recurrent gouty arthritis over a mean period of five years in 208 gouty subjects. Ann Intern Med. 1961;55:179-192.

• 摘要

88.  Hench PS. The diagnosis of gout and gouty arthritis. J Lab Clin Med. 1936;220:48.

89.  Krishnan E, Akhras KS, Sharma H, et al. Serum urate and incidence of kidney disease among veterans with gout. J Rheumatol. 2013;40:1166-1172.

• 全文
• 摘要

90.  Kuo CF, Grainge MJ, Mallen C, et al. Effect of allopurinol on all-cause mortality in adults with incident gout: propensity score-matched landmark analysis. Rheumatology (Oxford). 2015;54:2145-2150.

• 全文
• 摘要

91.  Kelley's textbook of rheumatology. 6th ed. Philadelphia, PA: W.B. Saunders Company; 2001.

92.  Lin KC, Lin HY, Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol. 2000;27:1501-1505.

• 摘要

93.  Humphreys BD, Soiffer RJ, Magee CC. Renal failure associated with cancer and its treatment: an update. J Am Soc Nephrol. 2005;16:151-161.

• 全文
• 摘要